06/13/22 9:00 AMNasdaq : GOVX, GOVXW managementhigh shortlow floatGeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business DevelopmentGeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced theRHEA-AIneutral
06/07/22 9:00 AMNasdaq : GOVX, GOVXW conferenceshigh shortlow floatGeoVax to Present at BIO International Convention 2022GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancerRHEA-AIneutral
05/25/22 1:47 PMNasdaq : GOVX, GOVXW high shortlow floatGeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq RulesGeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that it has entered into a definitive agreement with a single healthcare-focusedRHEA-AIneutral
05/24/22 9:00 AMNasdaq : GOVX, GOVXW high shortlow floatGeoVax Receives Notice of Allowance for Cancer Vaccine Patent in ChinaGeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer,RHEA-AIneutral
05/04/22 9:00 AMNasdaq : GOVX, GOVXW conferenceshigh shortlow floatGeoVax Announces Upcoming Presentations at Scientific Conferencesvia NewMediaWire –GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today that it will be represented during presentations at the followingRHEA-AIneutral
04/27/22 4:00 PMNasdaq : GOVX, GOVXW earningshigh shortlow floatGeoVax Reports 2022 First Quarter Financial Results and Provides Corporate UpdateGeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, todayRHEA-AIneutral
04/26/22 9:00 AMNasdaq : GOVX, GOVXW high shortlow floatGeoVax Announces Issuance of Malaria Vaccine PatentGeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies againstRHEA-AIneutral
04/19/22 9:00 AMNasdaq : GOVX, GOVXW conferencesearningshigh shortlow floatGeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate UpdateGeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, announces todayRHEA-AIneutral
04/18/22 5:52 PMNasdaq : GOVX, GOVXW IPOofferingacquisitionhigh shortlow floatCORRECTION - Aura FAT Projects Acquisition Corp. Announces Closing of Initial Public Offering and Exercise of Full Over-Allotment OptionIn a release issued under the same headline on Monday, April 18 th at 1:55 ET by GeoVax, Inc., please note that the release was distributed under the incorrect source and should have been sourced to Aura FAT Projects AcquisitionRHEA-AIneutral
04/18/22 4:05 PMNasdaq : GOVX, GOVXW IPOofferingacquisitionhigh shortlow floatAura FAT Projects Acquisition Corp. Announces Closing of Initial Public Offering and Exercise of Full Over-Allotment OptionAura FAT Projects Acquisition Corp. (the “Company”) announced today the closing of its initial public offering of 10,000,000 units at $10.00 per unit (the “Offering”). Each unit consists of one Class A ordinary share and oneRHEA-AIneutral
